ArticleOrphanet journal of rare diseases2025
Clinical and molecular characteristics of fructose 1, 6 bisphosphatase deficiency in 6 Egyptian patients and two common variants.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulation and clinical manifestations of gluconeogenesis dysfunction.npj metabolic health and disease · 2026Review
- Towards Next-Generation Sequencing as a First-Tier Diagnostic Test for Fructose-1,6-Bisphosphatase Deficiency.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFructose 1, 6 bisphosphatase (FBPase) deficiency is a rare autosomal recessive disease caused by mutations in the FBP1 gene. Symptoms of this disease are heterogeneous, with a variable age of onset, and are often confused with those of other inborn errors of metabolism. Biochemical testing is not conclusive, and patients usually need molecular testing for proper diagnosis and management. AIM OF STUDY: To describe clinical and molecular characteristics of patients with FBPase deficiency. PATIENTS AND
methodsThe study included six female patients diagnosed with FBPase deficiency, all recruited from the outpatient genetics clinic and the Children's Hospital at Ain Shams University, Faculty of Medicine. The mean age at presentation was 22.8 ± 16.16 months, while the mean age at diagnosis was 62 ± 45.16 months, indicating an average diagnostic delay of three years. The most common presenting symptoms were vomiting, fever, and lethargy. Hepatomegaly was the most frequently observed clinical sign on examination. Initial laboratory investigations commonly revealed ketotic hypoglycemia and metabolic acidosis. Molecular testing confirmed the diagnosis in all cases. Encouragingly, with appropriate management, all patients achieved normal neurocognitive outcomes.
conclusionFructose 1,6-bisphosphatase deficiency should be considered in children presenting with hypoglycemia and metabolic acidosis. Early molecular diagnosis is recommended to confirm the condition and to facilitate carrier screening and preventive strategies for at-risk family members.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.